tiprankstipranks
Trending News
More News >
APONTIS PHARMA AG (DE:APPH)
:APPH
Germany Market

APONTIS PHARMA AG (APPH) AI Stock Analysis

Compare
6 Followers

Top Page

DE

APONTIS PHARMA AG

(XETRA:APPH)

Rating:58Neutral
Price Target:
APONTIS PHARMA AG shows a solid financial foundation with strong revenue growth and equity stability. However, its potential is hampered by low profitability and high valuation. The stock's technical indicators show moderate upward momentum, but the high P/E ratio and lack of dividend yield suggest caution is warranted.

APONTIS PHARMA AG (APPH) vs. iShares MSCI Germany ETF (EWG)

APONTIS PHARMA AG Business Overview & Revenue Model

Company DescriptionAPONTIS PHARMA AG (APPH) is a specialty pharmaceutical company based in Germany, focusing on the development and marketing of Single Pill therapies. The company primarily serves the cardiovascular sector by providing innovative treatment solutions that simplify medication regimens, thereby improving patient adherence and outcomes. APONTIS PHARMA's core product offerings are designed to combine multiple active pharmaceutical ingredients into a single pill, targeting chronic diseases prevalent in the aging population.
How the Company Makes MoneyAPONTIS PHARMA AG generates revenue primarily through the sale of its Single Pill products to healthcare providers, pharmacies, and through partnerships with other pharmaceutical companies. The company's revenue model relies on its ability to develop effective combination therapies that are patented and marketed under its brand. Additionally, APONTIS PHARMA engages in strategic partnerships with other pharmaceutical firms to expand its product offerings and reach. Significant factors contributing to its earnings include the company's focus on chronic disease treatments, the growing demand for simplified medication regimens, and the proprietary nature of its Single Pill formulations.

APONTIS PHARMA AG Financial Statement Overview

Summary
APONTIS PHARMA AG demonstrates solid revenue growth and a strong equity base, reflecting a stable financial position. However, low net profitability and missing cash flow data present challenges. The company's financial health could benefit from improved profit margins and consistent cash flow reporting.
Income Statement
65
Positive
The company showed a positive revenue growth rate of 31% from 2023 to 2024, indicating strong sales momentum. Gross profit margin improved to 57.1% in 2024, highlighting cost efficiency. However, the net profit margin is low at 1.6%, and EBIT margin data is unavailable, pointing to potential profitability issues.
Balance Sheet
60
Neutral
The company has a strong equity ratio of 69.9% in 2024, indicating financial stability. However, the return on equity is modest at 2.4%, suggesting room for improvement in generating shareholder returns. The absence of debt in recent years reduces financial risk.
Cash Flow
50
Neutral
Operating cash flow data is missing for 2024, limiting full analysis. The company's free cash flow was not reported, creating uncertainty about cash generation efficiency. Historical trends show fluctuating cash flows, raising concerns about cash flow stability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue40.63M48.47M36.96M55.73M51.18M39.24M
Gross Profit798.74K27.70M23.17M34.99M33.79M25.03M
EBITDA-7.09M3.56M-12.94M5.67M1.99M1.04M
Net Income-7.08M753.57K-11.30M2.69M
Balance Sheet
Total Assets54.13M44.37M57.46M59.85M54.13M29.69M
Cash, Cash Equivalents and Short-Term Investments29.84M15.45M26.82M36.35M29.84M8.06M
Total Debt0.000.006.02M0.000.000.00
Total Liabilities13.42M13.36M27.20M18.29M13.42M26.23M
Stockholders Equity40.71M31.02M30.26M41.57M40.71M3.46M
Cash Flow
Free Cash Flow-9.97M7.74M1.77M721.45K
Operating Cash Flow-7.34M-12.60M11.02M3.43M1.45M
Investing Cash Flow-2.68M-2.90M
Financing Cash Flow-126.87K6.00M20.12M

APONTIS PHARMA AG Technical Analysis

Technical Analysis Sentiment
Negative
Last Price10.90
Price Trends
50DMA
11.29
Negative
100DMA
11.28
Negative
200DMA
10.30
Positive
Market Momentum
MACD
-0.18
Positive
RSI
37.73
Neutral
STOCH
59.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:APPH, the sentiment is Negative. The current price of 10.9 is below the 20-day moving average (MA) of 11.24, below the 50-day MA of 11.29, and above the 200-day MA of 10.30, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 37.73 is Neutral, neither overbought nor oversold. The STOCH value of 59.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:APPH.

APONTIS PHARMA AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
DEFME
68
Neutral
€14.32B23.164.37%2.96%0.10%27.83%
64
Neutral
€7.37B21.020.61%1.92%1.18%-29.88%
62
Neutral
€25.99B-9.56%0.36%-0.92%-4.30%
DEMRK
59
Neutral
€48.87B17.349.74%1.96%2.38%3.49%
58
Neutral
€92.23M119.892.46%31.12%
57
Neutral
€1.40B44.96-4.72%0.27%-18.82%-113.85%
DEEVT
48
Neutral
€1.29B-20.51%1.50%-127.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:APPH
APONTIS PHARMA AG
10.85
2.39
28.25%
DE:FME
Fresenius Medical Care AG & Co. KGaA
48.32
13.45
38.59%
DE:BAYN
Bayer
26.36
0.28
1.06%
DE:EVT
Evotec
7.35
-2.36
-24.27%
DE:MRK
Merck KGaA
112.70
-37.13
-24.78%
DE:BIO3
Biotest
29.60
2.60
9.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 25, 2025